idarubicin has been researched along with Kahler Disease in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.88) | 18.7374 |
| 1990's | 15 (44.12) | 18.2507 |
| 2000's | 16 (47.06) | 29.6817 |
| 2010's | 1 (2.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Agazzi, A; Bertolini, F; Greco, P; Laszlo, D; Mancuso, P; Martinelli, G; Pruneri, GC; Santoro, P | 1 |
| Lachmann, H; Myers, B; Russell, NH | 1 |
| Fruehauf, S; Goldschmidt, H; Hartschuh, W; Ho, AD; Moehler, T; Neben, K; Witzens, M | 1 |
| Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M | 1 |
| Gieseler, F; Glasmacher, A; Goldschmidt, H; Haferlach, T; Mezger, J; Schmidt-Wolf, IG | 1 |
| Anderson, S; Clark, RE; Cook, G; Franklin, IM; Lucie, NP; Morris, TC; Paul, J; Robertson, M | 1 |
| Balestri, F; Biscardi, M; Budriesi, R; Caporale, R; Gavazzi, S; Grossi, A; Scappini, B; Teodori, E | 1 |
| Aul, C; Fenk, R; Haas, R; Heyll, A; Hildebrandt, B; Huenerlituerkoglu, AN; Kobbe, G; Kropff, M; Schneider, P; Steidl, U | 1 |
| Baldacci, E; Capria, S; de Propris, MS; Meloni, G; Petrucci, MT; Pulsoni, A; Ribersani, M | 1 |
| McKenna, KE; Morris, TC; Ramadan, KM | 1 |
| Banerjee, SS; Eyden, B; Roy, A; Shenjere, P | 1 |
| Cook, G; Franklin, IM; Sharp, RA; Tansey, P | 1 |
| Hegewisch-Becker, S; Hossfeld, DK | 1 |
| Cattan, AR; Maung, ZT | 1 |
| Ascari, E; Barbarano, L; Bergonzi, C; Brugnatelli, S; Cavanna, L; De Paoli, A; Giordano, M; Petrini, M; Riccardi, A; Ucci, G | 1 |
| Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Hiemenz, JW; Kronish, L; Moscinski, LC; Saba, HI; Spiers, AS; Sullivan, P; Zorsky, PE | 1 |
| Clemens, MR; Gieseler, F; Glasmacher, A; Gorschlüter, M; Haferlach, T; Hahn, C; Kleinschmidt, R; Ko, Y; Maintz, C; Mezger, J; Ubelacker, R | 1 |
| Aul, C; Bauser, U; Fischer, J; Frick, M; Heyll, A; Kobbe, G; Quenzel, EM; Rieth, C; Schneider, P; Söhngen, D; Südhoff, T; Thiele, KP; Wehmeier, A; Wernet, P | 1 |
| Alcorn, MJ; Cook, G; Farrell, E; Franklin, IM; Marinaki, P; Pearson, C; Sharp, RA; Tansey, PJ | 1 |
| Borchmann, P; Diehl, V; Engert, A; Hübel, K; Kröger, B; Schnell, R; Tesch, H | 1 |
| Aul, C; Bauser, U; Heyll, A; Kobbe, G; Quenzel, EM; Schneider, P; Schneider, W; Söhngen, D | 1 |
| Bardhan, G; Ganguly, K; Kashyap, S; Majumdar, G | 1 |
| Bloem, AC; Lokhorst, HM; Roovers, DJ; van Vliet, M | 1 |
| Kulkarni, S; Mainwaring, PN; Powles, RL; Raje, N; Ramiah, V; Sumpter, K; Treleaven, J | 1 |
| Dunkley, S; Gibson, J; Iland, H; Joshua, D; Li, C | 1 |
| Boots, M; Giles, C; Kelsey, SM; Littlewood, TJ; Mills, MJ; Parameswaran, R; Samson, D | 1 |
| Capria, S; Ferrazza, G; Mandelli, F; Meloni, G; Micozzi, A; Petrucci, MT; Simone, F; Trasarti, S; Trisolini, SM | 1 |
| Crooks, RL; Granter, N; Lincz, LF; Spencer, A; Way, SL | 1 |
| Nilsson, B; Rödjer, S; Westin, J | 1 |
| Clark, AD; Cook, G; Douglas, KW; Franklin, IM; McQuaker, IG; Mitchell, LD; Parker, AN; Tansey, PJ | 1 |
| Alberts, AS; Falkson, G; Rapoport, BL; Uys, A | 1 |
| Capnist, G; Chisesi, T; de Dominicis, E; Dini, E | 1 |
| Eridani, S; Pearson, TC; Singh, AK; Slater, NG | 1 |
1 review(s) available for idarubicin and Kahler Disease
| Article | Year |
|---|---|
The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives.
Topics: Drug Resistance, Multiple; Forecasting; Gene Expression; Humans; Idarubicin; Leukemia; Lymphoma; Multiple Myeloma; Phenotype; Prognosis | 1996 |
17 trial(s) available for idarubicin and Kahler Disease
| Article | Year |
|---|---|
Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Vincristine | 2004 |
A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma; Survival Rate; Treatment Outcome; Vincristine | 2004 |
High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Idarubicin; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning | 2005 |
A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capsules; Dexamethasone; Doxorubicin; Female; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Vincristine | 1996 |
Oral idarubicin and prednisone for advanced, previously untreated, multiple myeloma: a pilot study. Cooperative Group of Study and Treatment of Multiple Myeloma.
Topics: Administration, Oral; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Humans; Idarubicin; Middle Aged; Multiple Myeloma; Pilot Projects; Prednisone; Survival Rate; Treatment Outcome | 1996 |
Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Etoposide; Female; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma; Neutropenia; Survival Rate; Treatment Outcome | 1997 |
Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Idarubicin; Immunoglobulin A; Immunoglobulin G; Immunoglobulin Isotypes; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Survival Rate; Vincristine | 1997 |
Idarubicin, melphalan and cyclophosphamide: an intensified high-dose regimen for the treatment of myeloma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Idarubicin; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Tachycardia, Supraventricular | 1997 |
Peripheral blood progenitor cell mobilisation in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Male; Mesna; Middle Aged; Multiple Myeloma; Remission Induction | 1997 |
A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Immunoglobulin A; Immunoglobulin G; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recombinant Proteins; Recurrence | 1997 |
Low dose oral idarubicin in combination with cyclophosphamide and dexamethasone (CID) for management of melphalan-prednisolone (MP) resistant myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma | 1999 |
Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Humans; Idarubicin; Methylprednisolone; Middle Aged; Multiple Myeloma; Remission Induction; Salvage Therapy; Thrombocytopenia; Treatment Failure; Vincristine | 1999 |
High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Melphalan; Middle Aged; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous | 2000 |
Tumour kinetics in multiple myeloma before, during, and after treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cell Count; Cell Division; Cyclophosphamide; Dexamethasone; Female; Gene Rearrangement; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunoglobulin Heavy Chains; Kinetics; Leukapheresis; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Neoplasm, Residual; Neoplastic Cells, Circulating; Transplantation, Autologous | 2001 |
Do anthracyclines have a role in the therapy of multiple myeloma?
Topics: Aged; Aged, 80 and over; Agranulocytosis; Antibiotics, Antineoplastic; Disease Progression; Female; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma; Recurrence; Remission Induction; Salvage Therapy; Thrombocytopenia; Treatment Failure | 2000 |
Dose escalation therapy in previously untreated patients with multiple myeloma following Z-Dex induction treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Interferon alpha-2; Interferon-alpha; Male; Melphalan; Middle Aged; Multiple Myeloma; Recombinant Proteins; Survival Rate; Treatment Outcome | 2002 |
A phase II study of idarubicin and prednisone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma; Prednisone; Survival Rate | 1990 |
16 other study(ies) available for idarubicin and Kahler Disease
| Article | Year |
|---|---|
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
Idarubicin containing regimen in multiple myeloma: preliminary results of a pilot study using a modified "TANDEM" transplant program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytomegalovirus Infections; Female; Humans; Idarubicin; Legionnaires' Disease; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Remission Induction; Transplantation Conditioning; Transplantation, Autologous | 2003 |
Novel combination chemotherapy for primary (AL) amyloidosis myeloma: clinical, laboratory and serum amyloid-P protein scan improvement.
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Idarubicin; Middle Aged; Multiple Myeloma; Serum Amyloid P-Component | 2003 |
Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Humans; Idarubicin; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Thalidomide; Vasculitis, Leukocytoclastic, Cutaneous; Vincristine | 2004 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoiesis; Humans; Idarubicin; Ifosfamide; Infections; Male; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine; Whole-Body Irradiation | 2004 |
Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Antibiotics, Antineoplastic; Aorta; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Guinea Pigs; Heart Atria; Humans; Idarubicin; K562 Cells; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Organ Culture Techniques; Verapamil | 2006 |
High-dose idarubicin, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma responsive to DAV chemotherapy: comparison with a historical control.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Dacarbazine; Female; Graft Survival; Humans; Idarubicin; Infections; Male; Melphalan; Middle Aged; Mucositis; Multiple Myeloma; Neutropenia; Nimustine; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2006 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |
Pseudo-Gaucher cells in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Dexamethasone; Diagnosis, Differential; Gaucher Disease; Histiocytes; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma; Plasma Cells | 2008 |
A comparison of a CB17 scid mouse model and the tetrazolium-dye assay using human haematological tumour cell lines.
Topics: Animals; Antineoplastic Agents; Burkitt Lymphoma; Coloring Agents; Daunorubicin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Experimental; Male; Mice; Mice, SCID; Multiple Myeloma; Tetrazolium Salts; Toxicity Tests; Tumor Cells, Cultured | 1996 |
[High-dose chemotherapy of patients with multiple myeloma].
Topics: Adult; Antibiotics, Antineoplastic; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Middle Aged; Multiple Myeloma | 1998 |
Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Idarubicin; Multiple Myeloma; Tumor Cells, Cultured; Verapamil | 1999 |
Acute promyelocytic leukaemia complicating multiple myeloma: evidence of different cell lineages.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Lineage; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Clone Cells; Combined Modality Therapy; Diphosphonates; Embryonal Carcinoma Stem Cells; Female; Gene Rearrangement, B-Lymphocyte, Light Chain; Humans; Idarubicin; Immunoglobulin kappa-Chains; Leukemia, Promyelocytic, Acute; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Neoplasms, Multiple Primary; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Osteolysis; Pamidronate; Prednisone; Remission Induction; Translocation, Genetic; Tretinoin | 1999 |
CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Idarubicin; Lomustine; Male; Middle Aged; Multiple Myeloma; Neutropenia; Pilot Projects; Recurrence; Survival Rate | 2000 |
A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Daunorubicin; Drug Evaluation; Female; Humans; Idarubicin; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nausea; Thrombocytopenia | 1988 |
Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Antineoplastic Agents; Daunorubicin; Female; Humans; Idarubicin; Injections, Intravenous; Leukemia; Lymphoma; Male; Middle Aged; Multiple Myeloma; Pilot Projects | 1985 |